Literature DB >> 31288256

Large-duct cholangiopathies: aetiology, diagnosis and treatment.

Shyam Menon1,2, Andrew Holt1.   

Abstract

Cholangiopathies describe a group of conditions affecting the intrahepatic and extrahepatic biliary tree. Impairment to bile flow and chronic cholestasis cause biliary inflammation, which leads to more permanent damage such as destruction of the small bile ducts (ductopaenia) and biliary cirrhosis. Most cholangiopathies are progressive and cause end-stage liver disease unless the physical obstruction to biliary flow can be reversed. This review considers large-duct cholangiopathies, such as primary sclerosing cholangitis, ischaemic cholangiopathy, portal biliopathy, recurrent pyogenic cholangitis and Caroli disease.

Entities:  

Keywords:  biliary cirrhosis; biliary strictures; endoscopic retrograde pancreatography; portal hypertension; primary sclerosing cholangitis

Year:  2019        PMID: 31288256      PMCID: PMC6583582          DOI: 10.1136/flgastro-2018-101098

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  70 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  P Angulo; K D Lindor
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

Review 2.  Biliary complications of orthotopic liver transplantation.

Authors:  B Y Tung; M B Kimmey
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

3.  Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC).

Authors:  Ulrika Broomé; Hans Glaumann; Eva Lindstöm; Lars Lööf; Sven Almer; Hanne Prytz; Hanna Sandberg-Gertzén; Stefan Lindgren; Frans-Thomas Fork; Gunnar Järnerot; Rolf Olsson
Journal:  J Hepatol       Date:  2002-05       Impact factor: 25.083

4.  Peroral cholangioscopic treatment of hepatolithiasis: Long-term results.

Authors:  Tadahiro Okugawa; Toshio Tsuyuguchi; Sudhamshu K C; Takeshi Ando; Takeshi Ishihara; Taketo Yamaguchi; Hirokazu Yugi; Hiromitsu Saisho
Journal:  Gastrointest Endosc       Date:  2002-09       Impact factor: 9.427

5.  Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy.

Authors:  B Condat; F Pessione; S Hillaire; M H Denninger; M C Guillin; M Poliquin; A Hadengue; S Erlinger; D Valla
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

Review 6.  Precancerous lesions of intrahepatic cholangiocarcinoma.

Authors:  T Shimonishi; M Sasaki; Y Nakanuma
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

7.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

8.  In primary sclerosing cholangitis, gallbladder polyps are frequently malignant.

Authors:  Daniel C Buckles; Keith D Lindor; Nicholas F Larusso; Lydia M Petrovic; Gregory J Gores
Journal:  Am J Gastroenterol       Date:  2002-05       Impact factor: 10.864

9.  An endoscopic approach to biliary complications following orthotopic liver transplantation.

Authors:  Paul J Thuluvath; Tamer Atassi; John Lee
Journal:  Liver Int       Date:  2003-06       Impact factor: 5.828

Review 10.  The cholangiopathies: disorders of biliary epithelia.

Authors:  Konstantinos N Lazaridis; Mario Strazzabosco; Nicholas F Larusso
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

View more
  2 in total

1.  Progressing pancreaticobiliary medicine in the UK.

Authors:  Andrew R Hart; Gavin Johnson; Matthew T Huggett
Journal:  Frontline Gastroenterol       Date:  2019-06-10

2.  17q12 Recurrent Deletions and Duplications: Description of a Case Series with Neuropsychiatric Phenotype.

Authors:  Roberta Milone; Raffaella Tancredi; Angela Cosenza; Anna Rita Ferrari; Roberta Scalise; Giovanni Cioni; Roberta Battini
Journal:  Genes (Basel)       Date:  2021-10-21       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.